Nano-antioxidant Drug in the Prevention, Control and Treatment of Degenerative Eye Disease.


Oxidative damage of the retinal neuronal cells as a result of free radical generation is a complication associated with several ocular diseases like diabetes, age-related macular degeneration, cataract, glaucoma, and nowadays, considered the principal factor responsible for the initiation and progression of diabetic retinopathy. This ocular dysfunction can cause structural and functional changes to the tissues, increased vascular permeability, and disruption of blood-retinal barrier, apoptotic loss of retinal capillary cells, microvascular abnormalities and retinal neovascularization making the loss of vision inevitable. 
The use of topical antioxidants to treat or delaying oxidative stress-related ocular manifestations is still poorly explored, while current therapies may include invasive methods, e.g. laser photocoagulation, surgery or systemic treatments with side effects. Ocular antioxidant potential therapy represents a non-invasive, safe and less painful methodology.


The advantages are enormous as this therapeutic technique is not invasive whilst current gold standard therapeutics are. Advantages include, Comfort for the patient, secure administration, no collateral damages or side effects, increase bioavailability, increase drug retention time on ocular surface, control drug release, increased treatment effectiveness and the low cost associated with product development are some of the many advantages.

Potential comercial use/applications: 

Prevention, Control and Treatment of Degenerative Eye Disease.